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27 ABSTRACT
28 Dietary supplementation with CLA has been reported to alleviate the effect of colitis 
29 in mice, but the mechanisms involved need further exploration. The study aimed to 
30 investigate how orally administered CLA alleviates DSS-induced colitis in mice. CLA 
31 was administered at five different doses: 40 mg/d, 20 mg/d, 10 mg/d, 5 mg/d and 2.5 
32 mg/d. Doses of CLA at 10 mg/d and higher alleviated colitis symptoms and reduced 
33 inflammation induced by DSS, in which 40 mg/d, 20 mg/d and 10 mg/d CLA 
34 significantly increased the concentration of MUC2 and goblet cells, but neither 5 mg/d 
35 CLA nor 2.5 mg/d CLA had any effects. Meanwhile, 40 mg/d CLA and 20 mg/d CLA 
36 treatments significantly up-regulated the concentration of tight junction proteins (ZO-
37 1, occludin and claudin-3) and ameliorated epithelial apoptosis caused by DSS. 
38 Moreover, oxidative stress-related enzymes (SOD, GSH-PX, CAT) and inflammatory 
39 cytokines (TNF-α, IL-10, IL-6) were modulated by 40 mg/d CLA and 20 mg/d CLA. 
40 Furthermore, 40 mg/d CLA rebalanced the gut microbiota damaged by DSS, including 
41 reducing Bacteroides and increasing Bifidobacterium and Odoribacter. In conclusion, 
42 CLA supplementation alleviated DSS-induced colitis in a dose-dependent manner by 
43 modulating inflammatory cytokines and oxidation stress, maintaining the mucosal 
44 barrier and reverting microbiota changes.
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48
49 INTRODUCTION
50 Conjugated linoleic acid (CLA) was the positional and geometric isomers of linoleic 
51 acid. Twenty eight CLA isomers have been identified from milk, dairy and ruminant 
52 meat.1 The predominant isomer in dietary sources is cis9, trans11-CLA (c9, t11-CLA) 
53 which constitutes up to 90% of total CLA 2 and is associated with positive health 
54 benefits.3-5 Trans10, cis12-CLA (t10, c12-CLA) is another common isomer which 
55 accounts for 1-10% of total CLA from diet6 and is associated with anti-obesity effects.7-
56 9 CLA has demonstrated potent immunomodulatory effects that are exhibited in an 
57 isomer specific manner. These effects have been demonstrated in a wide range of 
58 inflammatory based disorders including inflammatory bowel disease (IBD),10, 11 
59 atherosclerosis12-14 and diabete.15-18 
60 IBD comprises Crohn’s disease (CD) and ulcerative colitis (UC); their main 
61 characteristic is intestinal mucosal inflammation, and patients may have frequent 
62 recurrences and severe clinical forms.19-21 Though the etiology of IBD is not fully 
63 understood, several factors, including intestinal barrier dysfunction, immunologic 
64 abnormalities, expansion of inflammatory mediators and oxidative stress are involved 
65 in the pathogenesis of IBD.22, 23 5-aminosalicylic acid (5-ASA), corticosteroids, 
66 particularly prednisone, hydrocortisone, and budenisonide, have yielded positive 
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67 results in IBD treatment by inhibiting inflammation.24, 25 However, prolonged use of 
68 this type of drug may result in other diseases such as hypertension, diabetes and 
69 osteoporosis.22, 25, 26 New therapies for IBD which differ from traditional 
70 pharmacological treatments are being investigated and include prebiotics and some 
71 microbial metabolites such as unsaturated fatty acids.27, 28 
72 It is worth noting that CLA has been shown to relieve IBD symptoms in animal 
73 models.10-11 Feeding DSS-challenged C57BL/6J mice and their PPARγ-knock-out 
74 derivatives 1% CLA-supplemented diets proved that CLA was able to reduce colitis by 
75 activating PPAR-γ.29 In C57BL/6J colitis mice, CLA supplementation (100 mg/kg/day) 
76 prevented colonic shortening, significantly reduced the disease activity index and NF-
77 kB expression, and caused an increase of PPAR-γ and trefoil factor family 3 (TFF3) 
78 expression.30 Evans et al.,31 found that administration of a CLA-supplemented diet (1 g 
79 CLA/100 g diet) to C57BL/6J colitis mice improved disease activity, decreased 
80 expression of tumor necrosis factor-α (TNF-α), and prevented colitis in part through a 
81 PPAR-γ-dependent mechanism. Furthermore, a diet supplemented with 1% CLA in 
82 C57BL/6J colitis mice reduced mucosal damage and inflammatory mediator infiltration 
83 suggesting a PPAR-γ-dependent mechanism mediated by macrophages.32 These studies 
84 differed in terms of CLA concentrations administered to mice. Furthermore, the exact 
85 amount of CLA ingested by the mice and the concentration of CLA entering the 
86 intestinal tract of mice remains unclear. Moreover, it is important to fully comprehend 
87 the mechanisms by which CLA relieves colitis.
88 Against this background, the aim of the current study were to identify biologically 
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89 effective concentrations of orally administered CLA in mice and to uncover new 
90 potential pathways by which CLA alleviates colitis. The results from this study 
91 elucidate the relationships between the oral dose of CLA, the CLA content reaching the 
92 colon and colitis remission effect and provides more mechanisms by which CLA 
93 relieves colitis.
94
95 MATERIALS AND METHODS
96 Animals and Experimental Design
97 Male C57BL6/J mice (n = 64), 8-week-old and weighing 22-24 g, were raised at 
98 room temperature (25°C±2°C) and photoperiod (12 h/12 h light/dark period) in the 
99 barrier facility of Animal Center of Jiangnan University. Then, the 64 mice 
100 were divided into 8 groups (n=8/group) and fed standard chow and sterile water.
101 Table 1 showed the experimental procedures. Briefly, 2.5% (w/v) DSS (molecular 
102 weight 36,000-50,000, MP Biomedicals, LLC, Irvine, CA, USA) was added to the 
103 drinking water to induce colitis; the control group was fed with 200 μL skim milk (13% 
104 w/v) daily; the medically treated group, termed mesalazine group received 200 μL 10 
105 mg/mL mesalazine (Etiasa pharmaceutical Co., Ltd., Saint-Cloud, Paris, France), while 
106 five CLA groups orally received 200 μL of different concentrations of CLA (emulsified 
107 with 13% w/v skim milk). CLA (50:50 mixture of c9, t11 and t10, c12 CLA isomers, 
108 purity: >99%, Nu-Check-Prep, Elysian, MN, USA) was emulsified with 13% w/v skim 
109 milk at different concentrations. The orally administered CLA concentrations were 40, 
110 20, 10, 5 and 2.5 mg/d, respectively. The protocol for present study was approved by 
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111 the Ethics Committee of Jiangnan University, China (JN.No20180615c0560730[109]) 
112 and complied with the Directive of 2010/63/ European Community.
113
114 Assessment of Colitis
115 During DSS treatment, the changes of body weight and the disease activity index 
116 (DAI) of mice were measured everyday as the method of previous literature.33, 34 Colon 
117 length was measured after dissecting the mice. Colon tissues were collected, dehydrated, 
118 embedded, sliced, and stained with Haematoxylin and Eosin (H&E) as the previous 




123 The freshly excised colon was rinsed, homogenized in tissue lysis buffer, and then 
124 centrifuged at 10,000 × g at 4 °C for 15 min. The change of myeloperoxidase (MPO) 
125 activity, cyclooxygenase 2 (COX-2) activity and inducible nitric oxide synthase (iNOS) 
126 activity in the colon were assessed by commercially available ELISA kits (Nanjing 
127 Senbeijia Biotechnology Co., Ltd., Nanjing, Jiangsu, China) according to the 
128 manufacturer’s instructions. The change of the colonic malonic dialdehyde (MDA), 
129 superoxide dismutase (SOD) activity, catalase (CAT) activity and glutathione 
130 peroxidase (GSH-PX) activity were assessed by the corresponding Kit (Nanjing 
131 Jiancheng Co., Ltd., Nanjing, Jiangsu, China). The protein concentration was measured 
132 by the BCA method using the BCA Protein Assay Kit (Beyotime Biotechnology, 
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133 Shanghai, China). The activities of MPO, COX-2, iNOS in the colon were presented as 
134 pictograms U/g colon protein, while that of SOD, CAT and GSH-PX were presented as 
135 pictograms U/mg colon protein. 
136
137 Alcian Blue and Periodic Acid-schiff (PAS) Staining
138 Distribution of mucin in the colon was investigated by alcian blue staining as the 
139 method of Steedman.37 The number of goblet cells was investigated by PAS staining as 
140 previously described.38
141
142 The Level of Cytokines in Colon Tissue
143 The concentrations of IL-4, TNF-α, IL-1β, IL-10 and IL-17 were measured by 
144 commercially available ELISA kits (R&D Systems, Minneapolis, MN, USA) in the 
145 supernatants of freshly isolated pieces of colon tissue homogenized with potassium-
146 phosphate buffer (1% protease inhibitor cocktail) and centrifuged at 10, 000 × g at 4 °C 
147 for 15 min. The protein concentration was measured by the BCA method using the BCA 
148 Protein Assay Kit (Beyotime Biotechnology, Shanghai, China) and the results were 
149 expressed as pg/mg protein of colon.
150
151 Measurement of Tight Junction Proteins
152 The concentrations of E-cadherin 1, occludin, ZO-1 and claudin-3 were measured by 
153 commercially available ELISA kits (Nanjing Senbeijia Biotechnology Co., Ltd., 
154 Nanjing, Jiangsu, China) in the supernatants of freshly isolated pieces of colon tissue 
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155 homogenized with potassium-phosphate buffer (1% protease inhibitor cocktail) and 
156 centrifuged at 10,000 × g at 4 °C for 15 min. The protein concentration was measured 
157 by the BCA method using the BCA Protein Assay Kit (Beyotime Biotechnology, 
158 Shanghai, China) and the results were expressed as pg/mg protein of colon.
159
160 Fatty Acid Analysis
161 The extraction and methylation of fatty acid in blood, liver and colon were performed 
162 as previous described.35, 39 Then, fatty acid were recovered with hexane and measured 
163 by GC-MS (the parameters of the instrument was described as previously described). 
164 35 The temperature programming of the gas chromatography was described as the 
165 method of Yang et al.40
166
167 Measurement of Transmission Electron Microscopy (TEM)
168 The integrity of the tight junction (TJ) proteins of epithelial cells was assessed by 
169 measuring TEM. Colon tissues were collected, immobilized, dehydrated, embedded, 
170 sliced, and stained as the previous method.41 Then, the sections were detected under 
171 HITACHI H8100 TEM (Hitachi, Tokyo, Japan) with an accelerating voltage of 200 kV.
172
173 DNA Extraction, PCR Amplification, Sequencing and Bioinformatics Analysis
174 Faecal samples from mice were collected to assess the changes in the composition of 
175 intestinal flora. Metagenomic DNA of the fecal samples was extracted by using a 
176 FastDNA Spin Kit for Feces (MP Biomedicals, LLC, Irvine, CA, USA). The V3-V4 
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177 region of the 16S rRNA gene was PCR amplified using primers (341F: 5′-
178 CCTAYGGGRBGCASCAG-3′; 806R: 5′-GGACTACNNGGGTATCTAAT-3′) as the 
179 method of Yang. et al.35 After sequencing, bioinformatics analysis of the 16S rRNA 
180 sequence data was conducted as previously described.42
181
182 Statistical Analysis
183 GraphPad Prism 7 and SPSS 22.0 were used to analyze date. P value of < 0.05 was 
184 considered to indicate statistical significance. Microbiota-related analyses were 
185 conducted by QIIME and R 3.5.0. Linear Discriminant Analysis Effect Size (LEfSe) 
186 were performed by python 2.7 and R 3.5.0. Network diagram of sample and OTU and 




191 CLA Improved the Colitis Symptoms
192 The changes of body weight and DAI were measured daily during DSS treatment. 
193 Body weight of mice dropped significantly (Figure 1A) while the DAI rose 
194 continuously (Figure 1B) due to DSS treatment. DSS treatment resulted in 12.3% 
195 weight loss at the end of the trial compared with the animals’ initial weight (Figure 1A). 
196 However, the body weight of the mice in control group showed no significant difference. 
197 Compared with the DSS group, the weight loss of all the five CLA groups showed no 
198 significant difference.
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199 Treatment with different concentrations of CLA had different effects on DAI. The 
200 DAI increased to 10.50 ± 0.38 in the DSS group. The alleviating effects of mesalazine 
201 (DAI=7.13 ± 0.34, P < 0.01), 40 mg/d CLA (6.13 ± 0.61, P < 0.01), 20 mg/d CLA (7.12 
202 ± 0.64, P < 0.01) and 10 mg/d CLA (7.37 ± 0.72, P < 0.05) on colitis were significant 
203 when compared with the DAI of the DSS group (Figure 1B). 5 mg/d CLA and 2.5 mg/d 
204 CLA treatment led to an insignificant decrease in the DAI (8.87 ± 0.48, 9.25 ± 0.31) 
205 compared with the DSS treatment.
206 The colon length in the control group was 7.11 ± 0.18 cm (Figure 1C). The colons 
207 was normal reddish and the feces was granular in the control group. In comparison, the 
208 colon length of DSS-treated mice was 5.8 ± 0.12 cm, which showed dark red colons, 
209 swollen, bleeding intestinal wall (Figure 1D). DSS treatment led to a 16.4% reduction 
210 of colon length compared with the control group, whereas mesalazine, 40 mg/d CLA, 
211 20 mg/d CLA and 10 mg/d CLA treatments prevented the colon shortening process by 
212 5.6%, 5.4%, 5.5% and 9.5%, respectively (Figure 1C). Thus, mesalazine, 40 mg/d CLA, 
213 20 mg/d CLA and 10 mg/d CLA treatment could significantly prevent colon shortening, 
214 but 5 mg/d CLA and 2.5 mg/d CLA could not, consistent with the results of DAI.
215
216 CLA Recovered the Damage in Colonic Tissue Caused by DSS and Regulated 
217 Inflammatory Enzymes
218 H&E staining was used to evaluate the histopathological injury. The colons of normal 
219 mice had intact mucous membranes and neat villi with healthy crypt structure (Figure 
220 2A). The colon tissue of normal mice was enriched in goblet cells without inflammatory 
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221 cell infiltration or mucosal erosion. However, the mice in the DSS group showed 
222 intestinal mucosa and submucosal edema, severe inflammatory cell infiltration, crypt 
223 loss and epithelial injury.
224 The colon injury score of the DSS-treated mice (13.75 ± 0.25) was significantly 
225 higher than that of the normal mice (1.38 ± 0.38) (P < 0.0001) (Figure 2B). 40 mg/d 
226 CLA and mesalazine treatment significantly improved the inflammation of colon, and 
227 tissue damage was reduced to different extents in the 20 mg/d CLA and 10 mg/d CLA 
228 groups. Among all the groups, 40 mg/d CLA and mesalazine treatment showed more 
229 effects of protecting colon: the crypts were intact and no significant disappearance for 
230 the goblet cells. Furthermore, 40 mg/d CLA and mesalazine treatment showed the least 
231 edema, and the least extent of inflammatory cell infiltration in the submucosa and 
232 serosa. The colon tissue injury scores of the mice treated with 40 mg/d CLA and 
233 mesalazine were 3.13 ± 0.29 and 4.00 ± 0.42, respectively, similar to that of the control 
234 group. Fossae deformation, partial loss of mucosal epithelial cells, structural damage of 
235 the muscular layer were found in the mice of 20 mg/d CLA and 10 mg/d CLA groups. 
236 However, 5 mg/d CLA and 2.5 mg/d CLA treatments did not protect against the colon 
237 tissue damage. The tissue injury score in 5 mg/d CLA and 2.5 mg/d CLA was 12.25 ± 
238 0.45 and 13.38 ± 0.38, close to DSS group.
239 In order to evaluate the effect of CLA on colonic inflammatory enzymes, MPO, 
240 COX-2, and iNOS activities were measured. Mesalazine, 40 mg/d CLA, 20 mg/d CLA, 
241 10 mg/d CLA, 5 mg/d CLA and 2.5 mg/d CLA treatment decreased the MPO activity 
242 induced by DSS from 4.83 ± 0.21 to 3.26 ± 0.16, 3.48 ± 0.26, 3.66 ± 0.29, 3.41 ± 0.54, 
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243 4.05 ± 0.27 and 3.99 ± 0.32 U/g, respectively (Figure 2C). Apart from 5 mg/d CLA and 
244 2.5 mg/d CLA groups, the MPO activity of mice in the other groups all showed 
245 significant differences when compared with the DSS group, which was consistent with 
246 the results of DAI and colon length. The DSS treatment resulted in highest COX-2 
247 activity (27.25 ± 1.934 U/g protein), while mesalazine, 40 mg/d CLA, 20 mg/d CLA 
248 and 10 mg/d CLA treatment significantly decreased COX-2 activity (22.58 ± 1.194, 
249 22.65 ± 1.039, 22.41 ± 0.964 U/g protein) (Figure 2D). Moreover, the iNOS activities 
250 of the mice of all the seven groups were lower than that of the DSS group, although the 
251 differences were not significant (Figure 2E).
252
253 CLA Protected the Intestinal Barrier
254 To evaluate the influence of CLA on the mucous layer and goblet cells, the 
255 concentration of mucin2 (MUC2) and goblet cell numbers were measured. The results 
256 of alcian blue and PAS staining showed that the goblet cells were severely damaged, 
257 and large amounts of MUC2 disappeared in DSS group (Figure 3A and 3B). Mesalazine, 
258 40 mg/d CLA, 20 mg/d CLA and 10 mg/d CLA treatments significantly protected the 
259 reduction of goblet cells and the destruction of mucosal layer.
260 The content of MUC2 was analyzed by ELISA. The concentration of MUC2 was 
261 significantly reduced in the mice of DSS treatment (66.74 ± 1.52 pg/mg protein), 
262 whereas 40 mg/d CLA and mesalazine treatment could maintain its content (80.53 ± 
263 3.783 and 78.50 ± 1.946 pg/mg protein, respectively) at normal levels compared with 
264 control (79.98 ± 1.48 pg/mg protein) (Figure 3C). Moreover, 20 mg/d CLA and 10 mg/d 
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265 CLA treatments significantly increased the content of MUC2 compared with the DSS 
266 group, while MUC2 in the 5 mg/d CLA and 2.5 mg/d CLA groups were similar to that 
267 of the DSS group. Remarkably, mice challenged with DSS suffered a loss of mucus-
268 producing goblet cells compared with untreated mice. However, 40 mg/d CLA, 20 mg/d 
269 CLA and 10 mg/d CLA treatments significantly relieved the loss of goblet cells at a 
270 reasonable level (p < 0.01) (Figure 3D). The concentration of MUC2 verified the above 
271 mentioned phenomenon (Figure 3C and 3D).
272 To evaluate the effect of CLA on the epithelium structure, TJ proteins and epithelial 
273 apoptosis were measured. Mesalazine, 40 mg/d CLA, 20 mg/d CLA, 10 mg/d CLA and 
274 5 mg/d CLA treatments increased the concentrations of ZO-1 by 20.7%, 50.7%, 51.9%, 
275 33.6% and 33.2%, respectively, compared with DSS treatment (Figure 4A). Moreover, 
276 DSS treatment decreased the concentration of E-cadherin 1, occludin and claudin-3 
277 compared with the control (Figure 4B, 4C, 4D). By contrast, 40 mg/d CLA and 20 mg/d 
278 CLA significantly increased the concentration of occludin and claudin-3. The 
279 concentrations of occludin and claudin-3 were up-regulated to certain levels in 10 mg/d 
280 CLA, 5 mg/d CLA and 2.5 mg/d CLA groups, but were not significantly different to 
281 DSS (Figure 4B and 4C). However, E-Cadherin1 levels in all the CLA groups were 
282 significantly higher than that in the DSS group (Figure 4D). 
283 To further verify that CLA can affect the tight junction of intestinal epithelial tissues,
284 TEM was used to observe the tight junction of intestinal epithelial tissues. In the control 
285 mice, intestinal barrier was intact, the microvilli (Mv) of the epithelial cells were neatly 
286 arranged, and TJ, adheres junction (AJ), desmosome (De) were integrate. However, 
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287 fractured a widened or fractured TJ, AJ and De, curated microvilli was observed in the 
288 DSS treated mice. These were improved significantly following 40 mg/d CLA 
289 treatment (Figure 4E), which showed that CLA can improve the TJ and AJ of intestinal 
290 epithelial tissues.
291 Furthermore, Hoechst 33258, a special fluorescent dye, was used to stain for the 
292 colon tissues. Hoechst 33258 could differentiate between apoptotic and normal cells by 
293 using a fluorescence microscope. The nuclei of normal cells show diffuse homogeneous 
294 blue fluorescence; however, apoptotic cells present with strong blue fluorescence. As 
295 expected, the control treatment did not induce apoptosis of cells, but when treated with 
296 DSS, typical morphological changes were observed, as the image displays, with nuclear 
297 fragmentation, chromosomal condensation and cell shrinkage (Figure 4F). 40 mg/d 
298 CLA, 20 mg/d CLA and mesalazine treatments could prevent apoptotic cells, while a 
299 large number of apoptotic cells appeared in the mice in 5 mg/d CLA and 2.5 mg/d CLA 
300 groups (Figure 4F).
301
302 CLA Regulated Oxidative Stress
303 In order to evaluate the influence of CLA on oxidative stress, MDA level, CAT 
304 activity, GSH-PX activity and SOD activity of colon were measured. 40 mg/d CLA and 
305 20 mg/d CLA treatment significantly increased SOD activity with a 1.22- and 1.20- 
306 fold compared with DSS treatment, respectively (Figure 5A). However, there was no 
307 significant difference among all the CLA groups and other groups for MDA (Figure 
308 5B). In addition, mesalazine, 40 mg/d CLA, 20 mg/d CLA and 10 mg/d CLA treatments 
Page 14 of 88
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
15
309 exhibited significant increments on GSH-PX activity (17.5%, 25.5%, 24.3% and 18.7%) 
310 (p < 0.05) compared with DSS treatment (Figure 5C). DSS and 20 mg/d CLA treatment 
311 showed the lowest (35.65 ± 1.11 U/mg protein) and the highest (45.1 ± 2.12 U/mg 
312 protein) CAT activity, respectively. Furthermore, mesalazine, 40 mg/d CLA, 10 mg/d 
313 CLA and 2.5 mg/d CLA treatments showed significant increments on CAT activity 
314 compared with DSS treatment (p < 0.05) (Figure 5D). 
315
316 CLA Regulated Inflammatory Cytokines
317 In order to evaluate the influence of CLA on inflammatory factors, TNF-α, IL-1β IL-
318 10 and IL-6 concentrations were analyzed by ELISA. Inflammatory factors in the colon 
319 of DSS-treated mice were significantly higher than those in the normal mice, with 
320 significant increases in TNF-α, IL-1β and IL-6 (Figure 6). Notably, IL-1β, the most 
321 significant pro-inflammatory cytokine, increased by 2.42-fold in the colon (Figure 6A). 
322 CLA-feeding decreased the concentrations of colonic TNF-α and IL-6 (Figure 6B and 
323 6C). Compared with the DSS treatment group, 40 mg/d CLA and 20 mg/d CLA 
324 treatment significantly decreased the concentration of TNF-α in the colon (Figure 6B). 
325 In mesalazine, 40 mg/d CLA and 20 mg/d CLA groups, the concentration of IL-6 in the 
326 colon was significantly lower than in the DSS group; however, no significant 
327 differences were observed for 10 mg/d CLA, 5 mg/d CLA, 2.5 mg/d CLA and DSS 
328 groups (Figure 6C). Mesalazine treatment significantly decreased the concentration of 
329 IL-1β, while the mice of all the CLA groups showed no significant reduction compared 
330 to that in the DSS group (Figure 6A). Moreover, the concentration of the anti-
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331 inflammatory cytokine, IL-10, in mesalazine, 40 mg/d CLA and 20 mg/d CLA groups 
332 increased to 52.7%, 57.1% and 33.6% compared with DSS group (35.26 ± 0.93 pg/mg 
333 protein), respectively (Figure 6D). Interestingly, 40 mg/d CLA, 20 mg/d CLA, 10 mg/d 
334 CLA and 5 mg/d CLA treatment significantly increaseed PPAR-γ concentration, while 
335 mesalazine treatment did not (Figure 6E). Overall, 40 mg/d CLA exerted the most 
336 significant inflammatory modulation effect, followed by mesalazine and 20 mg/d CLA.
337
338 Correlation between Tight Junction Proteins, Antioxidant Enzymes and 
339 Cytokines Regulated by CLA and Colitis Indices in Mice
340 In order to evaluate the relationship between tight junction proteins, antioxidant 
341 enzymes and cytokines regulated by CLA and colitis indices, the spearman correlation 
342 was analyzed. Different concentrations of CLA had different effects on the content of 
343 tight junction proteins, antioxidant enzymes and cytokines in mice colon tissue. The 
344 concentrations of ZO-1, occludin and E-Cadherin1 showed extremely negative 
345 correlations with DAI and tissue histological scores, while claudin-3 had no significant 
346 correlation with the colon length, MPO, DAI and tissue histological score (Figure 7A). 
347 Moreover, ZO-1 showed highly positive correlation with colon length, while occludin 
348 showed highly negative correlation with MPO.
349 In addition, the activity of GSH-PX and CAT displayed a high negative correlation 
350 with DAI and tissue histological scores. However, the concentration of MDA was the 
351 positive correlation with histological score and DAI. TNF-α and IL-6 showed high 
352 degree correlation with DAI and histological scores, but did not display correlation with 
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353 the colitis index MPO. Furthermore, IL-10 only showed negative correlation with 
354 histological score. IL-1β did not display correlation with any of the four colitis indices 
355 because CLA did not regulate it. It is notable that PPAR-γ displayed a high degree of 
356 correlation with colon length, DAI and tissue histological scores (Figure 7A).
357
358 The Effect of Orally Administered CLA on the Concentration of CLA in the Colon, 
359 Blood and Liver
360 In order to evaluate the distribution of orally administered CLA in mice, the CLA 
361 levels in colonic contents, blood and liver were analyzed. The concentrations of CLA 
362 in colonic contents from 40 mg/d CLA, 20 mg/d CLA, 10 mg/d CLA, 5 mg/d CLA and 
363 2.5 mg/d CLA groups were 1.347 ± 0.153, 0.743 ± 0.057, 0.614 ± 0.11, 0.443 ± 0.076, 
364 0.226 ± 0.092 g/100g FAME, respectively, which were higher than that in the control 
365 group as well as mesalazine and DSS groups (Figure 7B). Similar to that observed in 
366 the colon, CLA concentrations in blood and liver from the CLA groups showed a 
367 decreasing trend from 40 mg/d CLA to 2.5 mg/d CLA in line with the decreasing 
368 concentrations of CLA administered to the mice (Figure 7C and 7D). The 
369 concentrations of CLA in colonic, blood and liver samples from control, mesalazine 
370 and DSS treatment groups were not statistically different from each other (Figure 7B, 
371 7C and 7D).
372 In order to evaluate the effect of the concentration of CLA in the colon on 
373 inflammatory markers of colitis, the interdependent quantitative relationships between 
374 the colonic CLA concentration and inflammatory markers of colitis were analyzed via 
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375 unary linear regression. The concentration of colonic CLA displayed extremely 
376 negative correlations with DAI and tissue histological scores (p < 0.0001). Moreover, 
377 colonic CLA showed a high positive correlation with colon length, while a highly 
378 negative correlation correlated with MPO (p < 0.05). The results show that the amount 
379 of CLA reaching the colon directly correlated with the oral dose of CLA, and the 
380 content of CLA in the colon significantly and positively correlated with the relief effect 
381 of colitis. 
382
383 Modulation of Intestinal Microbiota by CLA
384 In order to evaluate the effect of CLA on the intestinal microbiota, the gut microbiota 
385 of mice treated with CLA at 40 mg/d, mesalazine group, DSS and control groups were 
386 investigated based on 16S rRNA-amplicon sequencing. Mice with chronic stress (DSS 
387 group) showed dramatic alteration of the gut microbial structure compared with the 
388 control. In the control group, the dominant phyla were Actinobacteria (19.27%), 
389 Bacteroidetes (32.16%), Firmicutes (36.41%) and Verrucomicrobia (5.75%) (Figure 
390 8A). However, DSS treatment significantly changed the composition of bacteria at the 
391 phylum level, and the relative abundance of Bacteroidetes increased to 68.83% and the 
392 relative abundances of Actinobacteria, Firmicutes and Verrucomicrobia decreased to 
393 3.76%, 16.70% and 2.06%, respectively (Figure 8A). Even though the relative 
394 abundance of Bacteroidetes in the CLA and mesalazine groups was higher than that in 
395 the control group, it was significantly decreased compared with the DSS group. 
396 Moreover, CLA treatment significantly increased the relative abundance of Firmicutes, 
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397 compared with DSS treatment. Alpha diversity was evaluated by Chao1 and Shannon 
398 index. After CLA treatment, Shannon index increased and was significantly different 
399 compared with microbiota from the DSS group, but Chao1 index showed no statistical 
400 differences compared with DSS treatment (Figure 8B and 8C). Beta diversity was 
401 reflected by principal coordinates analysis (PCoA) of weighted UniFrac distance. The 
402 results showed that the gut microbiota of DSS treatment mice was significantly 
403 different from the mice in the control group, and administration of CLA could remit the 
404 shift of gut microbiota induced by DSS treatment (Figure 8D). OTUs of all four groups 
405 were evaluated to identify the unique and shared genus. Different groups had their own 
406 distinct OTUs which were not shared with native controls. There were six, eight, eight 
407 and twenty-five distinct OTUs in control, DSS, mesalazine and CLA groups, while 
408 others OTUs were shared among those groups (Figure 8E). 
409 The gut microbiota diversity among different groups was analyzed by LEfSe (LDA 
410 Effect Size). The LDA score histogram was drawn to identify statistically significant 
411 biomarkers and reveal the dominant microorganisms in each group (Figure 9A and 9B). 
412 Dominant communities of five, seven taxa and six taxa were found in the DSS, 
413 mesalazine and CLA groups, respectively. Among them, Bacteroides and 
414 Bacteroidaceae were the dominant in the DSS group; S24_7 and Verrucomicrobia were 
415 the dominant in the mesalazine group; while Proteobacteria, Odoribacteraceae and 
416 Odoribacter were the dominant microbes in the CLA group (Figure 9B). Relative 
417 abundance of selected taxa showed that the abundance of S24-7, Bifidobacterium, 
418 Lactobacillus and Akkermansia significantly decreased in DSS treatment mice, but the 
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419 abundance of Bacteroides significantly increased (Figure 9C). Compared with the DSS 
420 group, CLA treatment mice showed an increased abundance of Bifidobacterium and 
421 Odoribacter (p < 0.05) and a significantly decreased abundance of Bacteroides (Figure 
422 9C). 
423 The effect of CLA treatment on bacterial interaction patterns were further analyzed. 
424 In DSS group, Clostridiaceae (OTU82) and Peptostreptococcaceae (OTU101) were the 
425 core microbes. Clostridiaceae correlated positively with Coriobacteriaceae (OTU20), 
426 Enterobacter (OTU172), Blautia (OTU93), Eubacterium (OTU124) and 
427 Paraprevotella (OTU39) (Figure 9D). Moreover, Peptostreptococcaceae had a positive 
428 correlation with Staphylococcus (OTU58), Clostridium (OTU122) and Trabulsiella 
429 (OTU180). In CLA treatment group, it was found that Enterobacteriaceae (OTU170) 
430 and Anaeroplasma (OTU194) were the core microbe. Enterobacteriaceae showed e 
431 positive correlation with Pseudomonas (OTU190), but negative correlation with 
432 Anaeroplasma (OTU194), Ruminococcus (OTU110), Oscillospira (OTU191), 
433 Bifidobacterium (OTU19), which was also the core microbe (Figure 9D). Thus, CLA 
434 treatment changed the core gut microtioa and their interaction pattern. 
435 Furthermore, the correlations among colonic CLA concentration, TJ proteins, 
436 differential microorganisms and inflammation markers were analyzed. Colon length, 
437 histological score, MPO and DAI were the most important indicators for colitis, and 
438 showed the bigger weightiness in the network analysis (Figure 9E). Colonic CLA 
439 concentration positively correlated with colon length, IL-10 and TJ proteins (occluding, 
440 ZO-1 and E-Cadherin1), in contrast, negatively correlated with Bacteroides, 
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441 histological score, DAI, MPO and pro-inflammatory cytokines (TNF-α, IL-1β). 
442 Interestingly, the relative abundance of Bacteroides were positively correlated with 
443 histological scores and DAI; however, it was negatively correlated with IL-10 and TJ 
444 proteins (occluding and ZO-1), indicating Bacteroides has a negative effect on colitis. 
445 It can be found that TJ proteins (occluding, ZO-1 and E-Cadherin1) had a negatively 
446 correlation with histological score, MPO and DAI. Furthermore, TNF-α and IL-10 
447 showed an important correlation with the indicator of colitis. Notably, there was no 




452 Salicylate, steroids, immunosuppressants, and anti-tnf-alpha drugs are traditionally 
453 used to treat patients with IBD. However, different response rates and potential side 
454 effects appeared in these therapies. Thus, exploring novel therapeutic and preventive 
455 approaches for IBD is important and has attracted increasing interest.43-47 A number of 
456 studies have demonstrated that CLA can ameliorate experimental IBD in mice and 
457 pigs.29-32, 48, 49 
458 In this study, some clinical symptoms in mice were significantly alleviated by 
459 administering CLA to mice for 7 days prior to DSS treatment and continuing CLA 
460 administration for another 7 days simultaneously with DSS treatment. In particular, 
461 treatments 40 mg/d CLA, 20 mg/d CLA and 10 mg/d CLA alleviated colon shortening, 
462 diarrhea and hematochezia. In addition, 40 mg/d CLA, 20 mg/d CLA and 10 mg/d CLA 
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463 treatments significantly mitigated intestinal mucosa and submucosal edema, 
464 inflammatory cell infiltration, crypt loss and epithelial injury resulting from DSS 
465 challenge. Thus, 40 mg/d CLA, 20 mg/d CLA and 10 mg/d CLA treatments 
466 significantly decreased DAI, histological injury score, and increased colon length, but 
467 5 mg/d CLA and 2.5 mg/d CLA treatments did not elicit these effects, which indicates 
468 that CLA relieves colitis in a dose-dependent manner.
469 The mucosal barrier, the first line of protection of the intestinal tract, is mainly 
470 composed of mucous layer and epithelial cell layer. It prevents intestinal bacteria toxins 
471 and other exogenous substances from invading the intestinal tissues and, subsequently, 
472 prevents intestinal mucosal injury.50 40 mg/d CLA, 20 mg/d CLA and 10 mg/d CLA 
473 treatments increased the concentration of MUC2, which could maintain the integrity of 
474 the colonic mucous layer and protect goblet cells. Moreover, the goblet cell numbers of 
475 the mice treated with 40 mg/d CLA, 20 mg/d CLA and 10 mg/d CLA were higher than 
476 that of DSS treated mice, which was consistent with the results of MUC2. TJ proteins 
477 of enterocytes predominantly regulate the integrity of the intestinal barrier and play an 
478 important role in IBD.51 In the present study, 40 mg/d CLA and 20 mg/d CLA treatment 
479 up-regulated TJ proteins (E-cadherin 1, ZO-1, claudin-3 and occluding). Thus, we 
480 conclude that to a certain extent high CLA concentrations can maintain the integrity of 
481 epithelium structure. A previous study by Wang and colleagues44 showed that 1% CLA 
482 added in the diet up-regulated the mRNA levels of MUC2, E-cadherin 1, claudin-3, 
483 ZO-1 and occludin in DSS-induced colitis mice. Therefore, oral administration of CLA 
484 (40 or 20 mg/d) up-regulates the concentration of these TJ proteins, which indicates 
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485 that appropriate concentrations of CLA can improve the intestinal barrier function. 
486 Furthermore, 10 mg/d CLA and 5 mg/d CLA treatments increased the concentration of 
487 E-cadherin 1 and ZO-1 (p < 0.05) compared with DSS treatment, while 2.5 mg/d CLA 
488 (2.5 mg/d) only increased the concentration of E-cadherin 1. Therefore, the regulation 
489 of CLA on TJ proteins occurred in a dose-dependent manner.
490 Oxidative stress can lead to abnormal oxygen free radical metabolism and excessive 
491 activation of apoptosis. Moreover, the oxygen free radicals lead to increase release of 
492 inflammatory mediators (such as cytokines and chemokines), which not only cause 
493 epithelial cell damage, but also aggravates oxidative stress, leading to the destruction 
494 of the intestinal mechanical barrier.52 Chinnadurai and colleagues found that feeding 
495 high CLA (19.54 mg/g fat) enriched ghee to rats during the pubescent period resulted 
496 in an increase in CAT and SOD enzyme activities both in blood and liver.53 Large 
497 yellow croaker fed with soybean oil-based diets plus 0.83% CLA significantly 
498 increased the activity of CAT and total antioxidant capacity (T-AOC) in liver.54 
499 Moreover, SOD, CAT and GSH-PX can ameliorate the peroxidation reactions in 
500 colitis.55 In the current study, CLA (40 and 20 mg/d) significantly increased the activity 
501 of CAT, SOD and GSH-PX in colon tissue, which indicated that CLA alleviated colitis 
502 by inhibiting oxidative stress. Moreover, 10 mg/d CLA treatment increased the 
503 activities of CAT and GSH-PX in the colon, while only CAT activity was increased by 
504 5 mg/d CLA and 2.5 mg/d CLA. Thus, CLA regulated oxidative stress related enzymes 
505 in a dose-dependent manner. 
506 IBD may be associated with uncontrolled, highly activated inflammation of the 
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507 intestinal mucosa. Studies have shown that the anti-inflammatory effect of CLA was 
508 mainly achieved by regulating the expression and activity of PPARγ.56 PPARγ is one 
509 of the three subtypes of PPARs ( PPARα、PPARβ/δ and PPARγ), in which PPAR-γ 
510 belongs to the nuclear receptor superfamily.57 PPARγ can inhibit the activation and 
511 nuclear import of NF-κB through the IkB-α pathway,58 in which NF-κB plays a key 
512 role in the regulation of the inflammatory response and pathogenesis of IBD. 
513 Hontecillas et al.,48 found that CLA can inhibit inflammation of the colon in a colitis 
514 model caused by pathogenic bacteria, and increase the expression of PPAR in the colon. 
515 Since then, Bassaganya-Riera et al.,29 used PPARγ knockout mice to prove that CLA 
516 was able to reduce colitis by activating PPARγ. In colon cancer cell lines HT-29 and 
517 Caco-2, CLA induced cell apoptosis by up-regulation of PPARγ.59 In the current study, 
518 40 mg/d CLA, 20 mg/d CLA, 10 mg/d CLA, 5 mg/d CLA and mesalazine increased the 
519 concentration of PPARγ, which was consistent with previous research. 
520 NF-κB pathway can be activated by TNF-α, which was produced by macrophages; 
521 at the same time, NF-κB could promote the secretion of TNF-α, IL-6 and IL-1β.60 In 
522 RAW264.7, a macrophage cell-line from mice, CLA reduced the mRNA expression 
523 levels of INF-γ, COX2, TNF-α, IL-1 and IL-6 genes through the PPARγ pathway.61 
524 Moreover, CLA significantly down-regulated the expression of TNF-α, IL-1β, IL-6 and 
525 up-regulated IL-10.44 In our current study, CLA (40 or 20 mg/d) decreased the 
526 concentration of TNF-α and IL-6 while increasing that of IL-10 in the colon, which 
527 may be due to the activation of PPARγ and the inhibition of NF-κB, thus resulting in a 
528 lower secretion of pro-inflammatory cytokines (TNF-α and IL-6). However, these pro-
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529 inflammatory cytokines were not up-regulated by 10 mg/d CLA, 5 mg/d CLA mg/d 
530 CLA treatments. Thus, inflammatory cytokines were regulated by CLA in a dose-
531 dependent manner.
532 It is known for that in healthy individuals a symbiotic relationship exists between the 
533 gut microbiota and host, and the gut microbiota is closely related to the pathogenesis of 
534 IBD.62 With PCoA analysis, it was found that the gut microbiota of DSS-treated mice 
535 was dramatically different from that of the control group, but CLA (40 mg/d) treatment 
536 mitigated gut microbiota shift induced by DSS challenge. At the phylum level, the 
537 relative abundance of Bacteroidetes in the DSS treatment group was 2.14 times more 
538 than that in the control group, while that in the CLA (40 mg/d) administered group 
539 significantly decreased compared with the DSS group. Moreover, CLA treatment 
540 increased the relative abundance of Verrucomicrobia, which was considered to be 
541 associated with the higher expression of MUC2.63 At the genus level, CLA treatment 
542 increased the abundance of Bifidobacterium and Odoribacter and significantly 
543 decreased the abundance of Bacteroides compared with DSS treatment. 
544 Bifidobacterium was reported to remit colitis.64 Moreover, Odoribacter was reduced as 
545 a result of DSS treatment, which could ameliorate ulcerative colitis, and may increase 
546 host inflammation by reducing production of short chain fatty acids.65 Most commonly, 
547 Odoribacter is known for of its ability to produce butyrate,66 which can improve the 
548 intestinal barrier and relieve colitis.67, 68 Notably, the current results showed that 
549 Odoribacter had a positive correlation with occludin and negative correlation with IL-
550 6. Some Bacteroides fragilis strains can invade intestinal tissue and cause damage.69 In 
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551 addition, certain B. vulgatus and B. ovatus have been found to affect the development 
552 of IBD.70-72 In the present study, the results showed that Bacteroides were negatively 
553 correlated with TJ proteins (occluding and ZO-1), IL-10 and positively correlated with 
554 inflammatory markers of colitis (DAI and histological score), which was consistent 
555 with previous results.70-72 
556 Sokol et al.,73 reported a skewed microbial interaction pattern in IBD patients and 
557 found that the concomitant analysis of microbiota showed a dense and homogenous 
558 correlation network in healthy subjects, but an unbalanced network in IBD patients. In 
559 the present study, unbalanced microbiota was found in DSS treatment group, in which 
560 the core microbes were Clostridiaceae, Peptostreptococcaceae, Staphylococcus, 
561 Trabulsiella and Paraprevotella, and correlated positively with Coriobacteriaceae, 
562 Enterobacter, Eubacterium. Additionally, Clostridiaceae, Peptostreptococcaceae, 
563 Staphylococcus, Trabulsiella, Enterobacter and Paraprevotella have been confirmed 
564 to aggravate colitis.74, 75 However, CLA treatment could improve the unbalanced 
565 microbiota. In CLA treatment group, Enterobacteriaceae, one of the core microbes, 
566 showed a positive correlation with Pseudomonas, but negative correlation with 
567 Anaeroplasma, Ruminococcus, Oscillospira and Bifidobacterium. Interestingly, 
568 Ruminococcus, Oscillospira and Bifidobacterium were reported to improve colitis.64, 74, 
569 75 Meanwhile, Oscillospira could produce butyrate to improve the intestinal barrier 
570 and relieve colitis,67, 68, 74 and Ruminococcus was negatively correlated with CD.75 Thus, 
571 our results indicated that CLA (40 mg/d) treatment partially prevented the microbiota 
572 changes induced by DSS. 
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573 Thus, orally administrated CLA resulted in some CLA entering the colon, where it 
574 acts as an anti-inflammatory agent. Interestingly, the present study found a significant 
575 positive correlation between CLA content in the colon and the relief effect of enteritis. 
576 When the oral dose of CLA exceeded 10 mg/d, 0.613 mg/mL CLA reached the colon, 
577 which has a relief effect on colitis; however, when the oral dose of CLA was 5 mg/d, 
578 0.443 mg/mL CLA reached the colon, showing no significant improvement in colitis. 
579 This suggests that CLA does have a dose-dependent relationship in relieving colitis. In 
580 view of the efficacy of CLA for mice, clinical trials investigating the efficacy of CLA 
581 in UC patients need to be conducted in the future. According to the effective dose of 
582 the current study and the dose conversion relationship between animals and humans, 
583 the oral dose of CLA in future clinical trials of UC patients should be more than 42 
584 mg/kg body weight. 
585 The primary mechanisms that CLA significantly ameliorated DSS-induced colitis 
586 involved in inhibiting pro-inflammatory factors, maintaining mucosal barriers, 
587 regulating oxidative stress and intestinal microbial damage. From all those results, it 
588 can found that CLA entered into the bowel lumen then decreased the abundance of 
589 Bacteroides and increased the abundance of Bifidobacterium, which could impact the 
590 concentration of AJ proteins and inflammatory cytokines. Furthermore, CLA that in the 
591 bowel lumen could improve antioxidant related enzymes, which could increase AJ 
592 proteins and improve intestinal barrier. Simultaneously, CLA could directly penetrate 
593 into the mucus layer and epithelial cells to regulate MUC2 and AJ proteins. 
594 Additionally, CLA could enter into the lamina propria in the mice treated DSS, then 
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595 reduced inflammation and regulated the cytokines. Thus, CLA could not only indirectly 
596 improve intestinal barrier and regulate inflammatory factors through the regulation of 
597 bacterial flora and oxidative stress, but also could directly regulate mucin and TJ protein 
598 as well as inflammatory factors, which could directly improve related indexes of colitis. 
599 These results will help us understand the mechanisms by which CLA alleviates colitis 
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881 Table 1 Animal model experimental design.
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Control 13% wt/v skim milk 200 μL once a day (day1-day14) 13% wt/v skim milk 200 μL once a day (day1-day14)
DSS 13% wt/v skim milk 200 μL once a day (day1-day7)                         2.5% (w/v) DSS in water+13% wt/v skim milk 200 μL once a day (day8-day14)
Medicine 10 mg/mL mesalazine 200 μL once a day (day1-day7) 2.5% (w/v) DSS in water+10 mg/mL mesalazine 200 μL once a day (day8-
day14)
CLA-1 200 mg/mL CLA 200 μL once a day (day1-day7) 2.5% (w/v) DSS in water+200 mg/mL CLA 200 μL once a day (day8-day14)
CLA-2 100 mg/mL CLA 200 μL once a day (day1-day7) 2.5% (w/v) DSS in water+100 mg/mL CLA 200 μL once a day (day8-day14)
CLA-3 50 mg/mL CLA 200 μL once a day (day1-day7) 2.5% (w/v) DSS in water+50 mg/mL CLA 200 μL once a day (day8-day14)
CLA-4 25 mg/mL CLA 200 μL once a day (day1-day7) 2.5% (w/v) DSS in water+25 mg/mL CLA 200 μL once a day (day8-day14)
CLA-5 12.5 mg/mL CLA 200 μL once a day (day1-day7) 2.5% (w/v) DSS in water+12.5 mg/mL CLA 200 μL once a day (day8-day14)
882
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Fig.1 Symptoms of DSS-induced colitis. (A) Body weight, (B) Disease activity index (DAI), (C) Colon length, 
(D) Macroscopic pictures of colons. *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001. All data 
are presented as mean ± SEM (n=8 mice per group). 
234x245mm (300 x 300 DPI) 
Page 42 of 88
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
 
Fig.1B 
189x173mm (300 x 300 DPI) 
Page 43 of 88
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
 
Fig.1C 
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Fig.2 Effect of CLA on the histological injury and enzyme activities in colon of colitis. (A) Histological 
examination, Scale bars, 200 and 50 μm, (B) Colonic histological injury, (C) MPO, (D) COX-2, (E) iNOS. *: p 
< 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001. All data are presented as mean ± SEM (n=8 mice 
per group). 
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Fig.3 Effects of CLA on the mucous layer. (A) Alcin blue staining, Scale bar = 200 μm (B) Histological 
sections of the colon (stained with PAS), Scale bars, 20 μm, (C) Concentration of MUC2, (D) The number of 
goblet cells. *: p < 0.05, **: p < 0.01, ***: p < 0.001. All data are presented as mean ± SEM (n=8 mice 
per group). 
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Fig.3B 
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Fig.3C 
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Fig.3D 
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Fig.4 Effects of CLA on TJ proteins in colon and apoptosis of colonic epithelial cells. (A) ZO-1, (B) Occludin, 
(C) Claudin-3, (D) E-Cadherin1, (E) TEM of intestinal epithelial tissues, tight junction (TJ), adheres junction 
(AJ), desmosome (De), microvilli (Mv). Scale bar = 1 μm, (F) apoptosis of colonic epithelial cells. Scale bar 
= 200 μm. *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001. All data are presented as mean ± 
SEM (n=8 mice per group). 
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Fig.4C 
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Fig.4D 
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Fig.4E 
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Fig.5. Effects of CLA on the activity of oxidative stress-related enzymes in colon. (A) SOD, (B) MDA, (C) 
GSH-PX, (D) CAT. *: p < 0.05, **: p < 0.01, ***: p < 0.001. All data are presented as mean ± SEM (n=8 
mice per group). 
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Fig.5B 
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Fig.5C 
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Fig.5D 
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Fig.6. Effects of CLA on inflammatory cytokines in colonic tissue. (A) IL-1β, (B) TNF-α, (C) IL-6, (D) IL-10 
and (E) PPARγ. *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001. All data are presented as 
mean ± SEM (n=8 mice per group). 
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Fig.6C 
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Fig.6D 
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Fig.6E 
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Fig.7. CLA concentration in different tissues and correlation of CLA and colitis indices. (A) Correlation 
analysis of colitis indices and different parameters. (B-D) CLA concentration in the colonic, blood and liver. 
(E-H) The interdependent quantitative relationships between the colonic CLA concentration and 
inflammatory markers, DAI, histological scores, colon length and MPO. *: p < 0.05, **: p < 0.01, ***: p < 
0.001, ****: p < 0.0001. All data are presented as mean ± SEM (n=8 mice per group). 
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Fig.7C 
197x186mm (300 x 300 DPI) 
Page 72 of 88
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
 
Fig.7D 
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Fig.7E 
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Fig.7F 
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Fig.8 Evaluation of illumina MiSeq sequencing data showing that CLA could modulate the overall structure of 
gut microbiota. (A) Microbial distribution at the phylum level, (B) Alpha diversity indicated by Chao1 index, 
(C) Shannon index, (D) PCoA, with extended functionality for labeling groups, with normal probability 
ellipsoids for different groups, (E) Network diagram of sample and OTU. *: p < 0.05, **: p < 0.01, ***: p < 
0.001, ****: p < 0.0001. All data are presented as mean ± SEM (n=8 mice per group). 
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Fig.8B 
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Fig.8C 
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Fig.8D 
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Fig.9 Effects of CLA on dominant microorganisms. (A) Cladogram. (B) Distribution histogram based on LDA, 
with a log LDA score above 3.0. Significant taxa are labeled and annotated with tags in the right panel. (C) 
Relative abundance of S24-7, Bifidobacterium, Lactobacillus, Akkermansia, Bacteroides and Odoribacter. (D) 
Effect of CLA treatment on bacterial-interaction patterns of the validation cohort. Bacterial abundances were 
analyzed using Spearman’s test. Only significant correlations (p-value < 0.05, |R2| > 0.6) are displayed 
with an edge. The edge colors indicate positive (red) or negative (green) correlations, which depended on 
Spearman’s correlation coefficient. The node size represents the weight. (E) Correlation analysis of the 
concentration of colonic CLA, significant taxa, colitis indices, tight junction proteins, antioxidant enzymes 
and cytokine in colon. Only significant correlations (p-value < 0.05, |r2| > 0.6) are displayed with an edge. 
The edge colors indicate positive (red) or negative (green) correlations, which depended on Spearman’s 
correlation coefficient. The node size represents the weight. n=8 mice per group. 
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Fig.9C 
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Fig.9D 
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Fig.9E 
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TOC Graphic The diagram illustrated the ways that CLA alleviates DSS-induced colitis in mice from four 
aspects: intestinal microorganisms, oxidation stress, intestinal barrier, inflammatory cytokines. 40 mg/d, 20 
mg/d and 10 mg/d CLA significantly increased the concentration of MUC2 and goblet cells. Meanwhile, 40 
mg/d CLA and 20 mg/d CLA treatments significantly up-regulated the concentration of tight junction 
proteins (ZO-1, occludin and claudin-3) and ameliorated epithelial apoptosis caused by DSS. Moreover, 
oxidative stress-related enzymes (SOD, GSH-PX, CAT) and inflammatory cytokines (TNF-α, IL-10, IL-6) 
were modulated by 40 mg/d CLA and 20 mg/d CLA. Furthermore, 40 mg/d CLA rebalanced the gut 
microbiota damaged by DSS, including reducing Bacteroides and increasing Bifidobacterium and 
Odoribacter. 
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